Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Islet transplantation has proven to be an effective treatment for type 1 diabetes (T1D) yet is hampered by the shortage of available tissue. Recently, two reports from a Viacyte multicenter clinical trial demonstrate the feasibility, safety, and potential efficacy of transplanting macro-encapsulated human stem cell-derived pancreatic endoderm cells into patients with T1D, highlighting the promise of a stem cell-based therapeutic approach.

More information Original publication

DOI

10.1016/j.cmet.2022.01.002

Type

Journal article

Publication Date

2022-02-01T00:00:00+00:00

Volume

34

Pages

193 - 196

Total pages

3

Keywords

Cell Differentiation, Diabetes Mellitus, Type 1, Endoderm, Humans, Islets of Langerhans Transplantation, Stem Cells